RZLT vs. CRVO, COYA, FGEN, VTGN, ABEO, CLRB, AMLX, DMAC, IMUX, and ADAG
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include CervoMed (CRVO), Coya Therapeutics (COYA), FibroGen (FGEN), Vistagen Therapeutics (VTGN), Abeona Therapeutics (ABEO), Cellectar Biosciences (CLRB), Amylyx Pharmaceuticals (AMLX), DiaMedica Therapeutics (DMAC), Immunic (IMUX), and Adagene (ADAG). These companies are all part of the "medical" sector.
Rezolute (NASDAQ:RZLT) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, community ranking, media sentiment and valuation.
CervoMed has higher revenue and earnings than Rezolute.
In the previous week, Rezolute had 9 more articles in the media than CervoMed. MarketBeat recorded 13 mentions for Rezolute and 4 mentions for CervoMed. CervoMed's average media sentiment score of 1.88 beat Rezolute's score of 0.38 indicating that CervoMed is being referred to more favorably in the news media.
Rezolute presently has a consensus price target of $8.80, indicating a potential upside of 138.48%. CervoMed has a consensus price target of $57.50, indicating a potential upside of 215.59%. Given CervoMed's higher probable upside, analysts plainly believe CervoMed is more favorable than Rezolute.
Rezolute received 53 more outperform votes than CervoMed when rated by MarketBeat users. However, 100.00% of users gave CervoMed an outperform vote while only 75.68% of users gave Rezolute an outperform vote.
CervoMed's return on equity of -45.48% beat Rezolute's return on equity.
Rezolute has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, CervoMed has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
83.0% of Rezolute shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 20.8% of Rezolute shares are held by company insiders. Comparatively, 2.0% of CervoMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
CervoMed beats Rezolute on 8 of the 13 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
